Eli Lilly and Company $LLY Holdings Lowered by Tributary Capital Management LLC

Tributary Capital Management LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,130 shares of the company’s stock after selling 30 shares during the period. Tributary Capital Management LLC’s holdings in Eli Lilly and Company were worth $881,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Forum Financial Management LP lifted its holdings in shares of Eli Lilly and Company by 5.2% during the second quarter. Forum Financial Management LP now owns 8,805 shares of the company’s stock valued at $6,864,000 after purchasing an additional 437 shares during the last quarter. Meadow Creek Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 129.8% in the 2nd quarter. Meadow Creek Wealth Advisors LLC now owns 3,960 shares of the company’s stock worth $3,087,000 after acquiring an additional 2,237 shares in the last quarter. Caliber Wealth Management LLC KS lifted its stake in Eli Lilly and Company by 23.9% in the 2nd quarter. Caliber Wealth Management LLC KS now owns 876 shares of the company’s stock worth $683,000 after acquiring an additional 169 shares in the last quarter. Birch Hill Investment Advisors LLC lifted its stake in Eli Lilly and Company by 131.7% in the 2nd quarter. Birch Hill Investment Advisors LLC now owns 600 shares of the company’s stock worth $468,000 after acquiring an additional 341 shares in the last quarter. Finally, Onyx Bridge Wealth Group LLC lifted its stake in Eli Lilly and Company by 5.6% in the 2nd quarter. Onyx Bridge Wealth Group LLC now owns 1,248 shares of the company’s stock worth $973,000 after acquiring an additional 66 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Guggenheim reissued a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, BMO Capital Markets upped their target price on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $812.33 on Thursday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $768.84 billion, a price-to-earnings ratio of 53.09, a P/E/G ratio of 1.14 and a beta of 0.47. The business’s 50-day simple moving average is $762.81 and its 200-day simple moving average is $766.75. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.